Revolution Medicines, Inc.
RVMDW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001628171
In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 17 sales; 22 institutions reported holding it in 13F filings for Q2 2026, worth $93.0M in total; no superinvestor holds it.
Other share classesRVMD
13F holders, Q1 2026
Institutional positions in Revolution Medicines, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −1 vs. Q4 2025
- Shares held
- 10.1M
- +1.35M (+15.4%) vs. Q4 2025
- Total value
- $17.8M
- +$9.67M (+118.7%) vs. Q4 2025
- New holders
- 2
- 6 more added
- Sold out
- 3
- 5 more reduced
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RVMDW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $93.0M |
| Q1 2026 | 23 | $17.8M |
| Q4 2025 | 24 | $8.15M |
| Q3 2025 | 22 | $2.40M |
| Q2 2025 | 23 | $2.12M |
| Q1 2025 | 24 | $298.5K |
| Q4 2024 | 24 | $1.31M |
| Q3 2024 | 25 | $654.7K |
| Q2 2024 | 25 | $623.7K |
| Q1 2024 | 24 | $1.21M |
| Q4 2023 | 22 | $1.62M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Revolution Medicines, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 200 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 90 | $161 | 0.00% | +30+50.0% | Added |
| TD Waterhouse Canada Inc. | 448 | $790 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 886 | $1.59K | 0.00% | +886 | New |
| Morgan Stanley | 2,216 | $3.97K | 0.00% | +2,216 | New |
| Toronto Dominion Bank | 10,000 | $17.9K | 0.00% | −111,862−91.8% | Reduced |
| Driehaus Capital Management LLC | 20,000 | $34.8K | 0.00% | −115,000−85.2% | Reduced |
| TD Asset Management Inc | 40,636 | $70.7K | 0.00% | 00.0% | Unchanged |
| Weiss Asset Management LP | 73,640 | $128.1K | 0.00% | 00.0% | Unchanged |
| Farallon Capital Management, L.L.C. | 120,085 | $208.9K | 0.00% | 00.0% | Unchanged |
| Davidson Kempner Capital Management LP | 150,000 | $261.0K | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 170,698 | $305.5K | 0.00% | +15,829+10.2% | Added |
| Bleichroeder LP | 200,000 | $358.0K | 0.06% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 250,000 | $447.5K | 0.01% | 00.0% | Unchanged |
| Lunate Capital Ltd | 450,000 | $805.5K | 0.67% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 500,000 | $895.0K | 0.00% | 00.0% | Unchanged |
| Caption Management, LLC | 517,685 | $926.7K | 0.04% | +417,685+417.7% | Added |
| Price T Rowe Associates Inc | 579,550 | $1.01M | 0.00% | −16,384−2.7% | Reduced |
| Aristeia Capital LLC | 583,615 | $1.03M | 0.02% | −41,320−6.6% | Reduced |
| Sculptor Capital LP | 958,822 | $1.70M | 0.02% | +780,715+438.3% | Added |
| D. E. Shaw & Co., Inc. | 1,580,345 | $2.75M | 0.00% | +125,450+8.6% | Added |
| LMR Partners LLP | 3,838,024 | $6.87M | 0.06% | +686,319+21.8% | Added |
| CSS LLC | 17,505 | – | – | −1,940−10.0% | Reduced |
| Soros Capital Management LLC | 0 | $0 | 0.00% | −364,824−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −17,617−100.0% | Sold out |
| Ground Swell Capital, LLC | 0 | $0 | 0.00% | −13,613−100.0% | Sold out |